Clinical study design of a multicenter, prospective, randomized controlled clinical trial on clinical efficacy of Toripalimab adjuvant therapy on esophageal squamous cell carcinoma patients with post-neoadjuvant positive lymph node staging
10.3760/cma.j.cn115610-20210413-00180
- VernacularTitle:食管鳞癌新辅助治疗后淋巴结阳性病人行特瑞普利单克隆抗体辅助治疗的多中心、前瞻性、随机对照临床研究设计
- Author:
Liang DAI
1
;
Yongbo YANG
;
Qiuling SHI
;
Mengying FAN
;
Wanpu YAN
;
Keneng CHEN
Author Information
1. 北京大学肿瘤医院胸外一科 恶性肿瘤发病机制及转化研究教育部重点实验室 100142
- Keywords:
Esophageal neoplasms;
Squamous cell carcinoma;
Neoadjuvant chemo-therapy;
Surgical therapy;
Immunotherapy
- From:
Chinese Journal of Digestive Surgery
2021;20(6):655-659
- CountryChina
- Language:Chinese
-
Abstract:
Neoadjuvant therapy has become the first choice for locally advanced esophageal carcinoma. Patients with post-neoadjuvant positive lymph node staging (ypN+) have poor prognosis, and there is no effective adjuvant therapy. Programmed death protein-1 (PD-1) antibody can obtain better clinical efficacy in the treatment of advanced esophageal cancer. The authors designed a multicenter, prospective, randomized controlled clinical trial of Toripalimab (PD-1 antibody) adjuvant therapy on esophageal squamous cell carcinoma patients with ypN+ after the treatment of neoadjuvant chemotherapy combined with surgical resection, in order to provide clinical practices for the adjuvant treatment of ypN+ patients.
